Mkts

Summit Therapeutics Inc.

NASDAQ: SMMT
$14.15-0.93 (-6.14%)
As of Nov 13, 4:00 PM ET

Key statistics

Day range
14.0615.20
52-week range
12.0729.23
Today
Open15.20
Previous close14.15
Volume3.21M
Valuation
Market cap11.32B
P/E ratio—
EPS (TTM)-1.12
Income & risk
Dividend / yield—
Beta-1.48
Avg volume5.52M
Discussion

SMMT News

Stories mentioning SMMT from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue0.00
Cost of Goods Sold
Gross Profit0.000.000.000.000.000.00
Operating Expenses
Research & Development132,61851,265
Sales General & Admin
Total Operating Expenses195,212224,925234,211568,43766,85165,61458,37859,617
Operating Income (Loss)(65,614)(58,378)(59,617)
Interest Income
Interest Expense
Other Expense0.00(53.00)0.000.000.00
Pretax Income
Tax Provision
Net Income (Loss)(189,424)(219,172)(231,793)(565,708)(62,913)(61,203)(56,254)(60,385)
Earnings Per Share (Basic)(0.24)(0.29)(0.31)(0.76)(0.09)(0.09)(0.08)(0.09)
Earnings Per Share (Diluted)(0.24)(0.29)(0.31)(0.76)(0.09)(0.09)(0.08)(0.09)
Weighted Average Shares Outstanding (Basic)775,458747,702743,416742,615738,076718,542726,656707,905
Weighted Average Shares Outstanding (Diluted)775,458747,702743,416742,615738,076718,542726,656707,905

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About SMMT

Summit Therapeutics Inc. (NASDAQ: SMMT) is a stock listed on the Nasdaq Stock Market under the ticker symbol SMMT. It last traded at $14.15 (Nov 13, 2026, 4:00 PM ET), down 6.1% on the day. That gives Summit Therapeutics a market capitalisation of $11.3B.

Over the past 52 weeks SMMT has traded between $12.07 and $29.23.

For the quarter ended Mar 31, 2026 it reported a net loss of $189.4M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—-$189.4M
Dec 31, 2025—-$219.2M
Sep 30, 2025—-$231.8M
Jun 30, 2025—-$565.7M

From Summit Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…